Merck & Co.
AWARDS
NEWS
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.
The DMC recommended the trial continue without changes in order to determine other dual-primary endpoints, such as event-free survival.
A new study identifies the risk factors that could help healthcare providers recognize patients being treated for diabetes who are most likely to have low blood sugar.
Merck will invest $680 million to build a manufacturing facility in Durham and expand an existing site in Wilson.
JOBS
IN THE PRESS